NYSE
CRL
Last Price
US $231.21
KEY FIGURES
MKT CAP
$11.1B
EPS
TTM
$-3.77
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
2.81x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
-5.74%
Return on equity
ROIC: 7.14%
Valuation History
-62.2X
Price to Earnings
EV/EBITDA: 48.5X
Cash flow
Profit margin
6.55%
(FY vs FY)
EBITDA Y/Y
-11.77%
(FY vs FY)
Cash flow Y/Y
6.41%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $231.21
-55.21%
Default assumptions
EBITDA Multiple
Fair Value
Market $231.21
-69.02%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Charles River Laboratories International, Inc. cash flow to debt ratio of 24.06% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Charles River Laboratories International, Inc.'s free cash flow has increased 3.37% from $501.61M last year to $518.49M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Charles River Laboratories International, Inc.'s debt to equity ratio is 1.04, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Charles River Laboratories International, Inc.'s debt has increased relative to shareholder equity from 0.79 last year to 1.04 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Charles River Laboratories International, Inc. has a net debt to EBITDA ratio of 6.94x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk
Financial stability - ICR.
Charles River Laboratories International, Inc.'s interest coverage ratio of 4.48 indicates that earnings with good margin can cover interest payments on company debt
Financial risk - Profit margin growth.
Charles River Laboratories International, Inc.'s profit margin has decreased (-1.90K%) in the last year from 0.25% to -4.59%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Charles River Laboratories International, Inc.'s short-term assets of $1.45G exceed its short-term liabilities of $1.12G
Decreasing performance - ROA.
Charles River Laboratories International, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Charles River Laboratories International, Inc.'s return on equity of -5.74%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Charles River Laboratories International, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Charles River Laboratories International, Inc. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Charles River Laboratories International, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Charles River Laboratories International, Inc. has a free cash flow yield of 4.66%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
Charles River Laboratories International, Inc.'s yearly earnings has decreased -1.50K% since last year from $10.30M to $-144.34M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
Charles River Laboratories International, Inc.'s yearly revenue has decreased -0.85% since last year from $4.05G to $4.02G, signaling decreasing performance
Increasing performance - ROIC.
ROIC 7.14% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Increasing performance - 3-year revenue CAGR.
Charles River Laboratories International, Inc.'s 3-year revenue CAGR of 0.33% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Charles River Laboratories International, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Charles River Laboratories International, Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 103.57 based on Discounted Cash Flow model
Overvalued - Earnings yield.
Charles River Laboratories International, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 71.64 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Charles River Laboratories International, Inc. has an EV/EBITDA ratio of 34.05x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Overvalued - PEG ratio value.
Charles River Laboratories International, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Charles River Laboratories International, Inc. has a price-to-book ratio of 3.79x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Charles River Laboratories International, Inc. has a price-to-sales ratio of 2.81x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue